BioSync\u2122 Precision Yeast Synthesis

The Gold Standard for Infant Nutrition & Gut Health.

Endotoxin-free, E. coli-free Human Milk Oligosaccharides at 99.9% purity. First FDA GRAS globally for LNTr II. Manufactured for Morika Bio.

BioSync™ 3rd-Gen Yeast Synthesis

Endotoxin-Free & E. coli-Free

Legacy HMO production relies on engineered E. coli expression systems, which carry inherent endotoxin (LPS) risk. Our BioSync™ platform uses a food-grade yeast chassis to produce pharmaceutical-grade HMOs with zero endotoxin contamination -- a critical safety advantage for infant nutrition that older bacterial systems cannot match.

Zero Endotoxin Risk

Yeast cells do not produce lipopolysaccharide (LPS) endotoxins, eliminating the most critical contamination vector in infant-grade ingredients. No costly endotoxin removal steps required.

E. coli-Free Production Chain

Complete elimination of gram-negative bacteria from the production chain. No risk of pathogenic contamination in final product.

99.9% Purity | pH 6.7 | Moisture < 0.2%

Standardized physical properties across all HMO variants. Verified by independent ISO 17025 accredited laboratories.

Fermentation laboratory
Manufactured for Morika Bio

Download Our Independent GRAS Conclusion Report

Distributed by Morika Bio | Human Milk Oligosaccharides (HMOs)

1

Enter your work email

2

Platform Comparison

BioSync™ Yeast vs. Legacy E. coli Systems

A direct comparison of our 3rd-generation yeast synthesis platform against traditional bacterial expression systems used by most competitors.

Parameter
BioSync™ Yeast
E. coli Systems
Host Organism
Food-grade Saccharomyces
Engineered E. coli
Endotoxin (LPS) Risk
None -- inherently absent
High -- requires removal
Regulatory Pathway
FDA GRAS (achieved)
Requires endotoxin validation
Downstream Purification
Simplified
Complex (LPS removal)
Scalability
Industrial (50,000L+)
Industrial
Purity Achievable
99.9% (HPLC)
95-99% (HPLC)

Data represents typical production parameters. Manufactured for Morika Bio.

Product Portfolio

Key HMO Variants

Each variant is produced under our BioSync™ platform and verified through Morika Bio Global Quality Unit.

Structural Reference

C₁₈H₃₂O₁₄

2'-Fucosyllactose (2'-FL)

Most abundant HMO in human milk

Purity (HPLC)99.9%
Structural Reference

C₂₆H₄₅NO₂₀

Lacto-N-neotetraose (LNnT)

Key bifidogenic factor

Purity (HPLC)99.9%
Structural Reference

C₂₀H₃₇NO₁₅

Lacto-N-triose II (LNTr II)

First FDA GRAS globally via BioSync™

Purity (HPLC)99.9%

Technical Data

Typical Certificate of Analysis Parameters

Standardized COA parameters across the HMO portfolio. Full batch-specific COAs available upon request through The Vault.

HMO COA Parameters (Standardized)

ParameterSpecification
Purity (HPLC)99.9%
pH (1% solution)6.7 Neutral
Moisture< 0.2%
Ash< 0.1%
Endotoxin (LPS)Zero Risk (Yeast Platform)
Residual SolventsMeets ICH Q3C
Heavy Metals (total)< 5 ppm
Microbial Count< 100 CFU/g
E. coliAbsent
SalmonellaAbsent / 25g

Application Areas

Designed for Critical Applications

Infant Formula

Gold-standard HMO supplementation for premium infant formula. Supports gut microbiome colonization and immune development. Endotoxin-free for maximum safety.

Adult Gut Health

Prebiotic supplementation for adult digestive wellness. Promotes beneficial Bifidobacterium growth and SCFA production.

Clinical Nutrition

Medical-grade HMOs for clinical nutrition products targeting immune modulation and gut barrier integrity.

Regulatory & Compliance

FDA GRAS (First globally for LNTr II)FSSC 22000ISO 9001:2015Halal CertifiedEU Novel Food CompliantGMP Compliant

All certifications verified through Morika Bio Global Quality Unit. Manufactured for Morika Bio.